Abstract

FORMULATION AND CHARACTERIZATION OF ETHYL CELLULOSE, EUDRAGIT RSPO AND EUDRAGIT RLPO LOADED MICROSPHERES WITH METFORMIN AND GLIPIZIDE: IN VITRO AND IN VIVO STUDIES

*Irin Dewan, Md. Maksud Al- Hasan, SM Ashraful Islam, Mahjabeen Gazi, Md. Alliul Islam and Md. Jahid Kazi

Abstract

Objective: The aim of the current exploration is to formulate and evaluate the metformin and glipizide, both are type II anti-diabetic agents, loaded microspheres with an objective to sustained release as well as improve bioavailability. Materials and method: Microspheres were prepared by solvent evaporation method using different rate retardant polymers including eudragit RSPO, eudragit RLPO and ethyl cellulose. Prepared microspheres were characterized by percent drug loading and drug entrapment efficiency, FTIR, DSC and SEM. UVSpectrophotometric method was applied to assay the microspheres and in vitro dissolution studies according to USP paddle method were carried out in phosphate buffer (pH 6.8) for 8 hours. Results: The in vitro release kinetics was studied in different mathematical release models. The best data fitted with the highest correlation coefficient (R2) for microspheres was obtained for Korsmeyer-Peppas model. The maximum and minimum release of metformin and glipizide were observed 87.02% to 59.35% and 27.31% to 11.37% for single and 85.28% to 60.05% and 26% to 15.95% for combination polymers loaded microsphere after 8 hours dissolution respectively. Percent of drug loading was varid from 7.09% to 17.06% and percent of drug entrapment efficacy varied from 57.87% to 88.51%. The SEM, FTIR and DSC studies used to of confirmed good spheres and smooth surface as well as interaction between drug and polymer. Different biochemical tests have also done on albino rats which showed better control of blood sugar and it proves that formulations have given sustained release effects. Conclusion: In vitro and in vivo studies showed that metformin and glipizide loaded microspheres might be a good candidate as sustained drug delivery system for treating type II diabetic.

Keywords: Metformin, glipizide, microspheres, eudragit RSPO, eudragit RLPO.